Hypoimmune, Allogeneic CD22-Directed CAR T Cells That Evade Innate and Adaptive Immune Rejection for the Treatment of Large B Cell Lymphoma Patients That Are Relapsed/Refractory to CD19-Directed CAR T Cell TherapyAdam Johnson, Terry J. Fry, Andrew McAlister et al.|Blood|2023Cited by 4